April 2014

Hematologic Malignancies Clinical Trials

Treatment of High Risk Smoldering Myeloma

ECOG 3A06. The standard approach for smoldering plasma cell myeloma is close observation. This trial is testing whether early treatment of patients with high risk smoldering myeloma improves outcomes and quality of life. Patients will be randomized to lenalidomide vs. observation. This trial is available at multiple locations throughout the UH network. Eligible patients are those who have high risk smoldering myeloma fulfilling both of the criteria below:

  • Bone marrow plasma cells ≥ 10% or sheets of plasma cells.
  • Abnormal serum free light chain ratio (< 0.26 or > 1.65).

For more information contact:
Erica Campagnaro, MD at

BCL2 Inhibition for High Risk Relapsed CLL

ABBV1913. Patients with 17p deletion have the worst prognosis among CLL patients, and response to B cell receptor signaling inhibitors is less than that observed in other cytogenetic subtypes. This trial will evaluate the efficacy of the BCL2 inhibitor ABT 199 in the treatment of CLL patients with deletion of chromosome 17p who have failed at least one line of therapy.

For more information contact:
Basem William, MD, MRCP (UK) at

Lenalidomide plus R-CHOP for DLBCL

ECOG 1412. Lenalidomide has demonstrated activity in the treatment of aggressive and indolent lymphomas. Early studies show its with R-CHOP has high degree of activity with acceptable toxicity profile. This randomized phase II study will compare R-CHOP with R-CHOP plus Lenalidomide (R2CHOP). Eligible patients are those diagnosed with advanced stage or bulky stage II DLBCL who have not yet received therapy. This trial is open at multiple institutions throughout the UH network.

For more information contact:
Paolo Caimi, MD at

Methoxyamine and Temozolomide in Patients with Advanced Solid Tumors

Case 1Y05. This phase I trial will determine the maximum tolerated dose of methoxyamine given in conjunction with temozolomide in patients with and without CNS disease. Patients must have a histologically confirmed solid tumor that is considered incurable and is not amenable to conventional surgical, radiation therapy or chemotherapy treatment programs. Cohort B includes patients with CNS disease (including recurrent or progressive malignant gliomas and/or brain metastatic disease). Brain metastases do not have to be new to participate in this trial. This phase 1 trial is open only at UH main campus.

For more information contact:
Jennifer Eads, MD at

Vaccine Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

A071101. This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person's own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery.

For more information contact:
Andrew Sloan, M.D. at

Treatment of Renal Tumors in Poor Surgical Candidates

CASE 12806. Radiosurgery is standard of care for renal tumors as they send x-rays directly to the tumor and cause less damage to normal tissue. This trial studies the side effects and best dose of giving sterotactic radiosurgery and to see how well it works in treating patients with renal tumors who are poor candidates for surgery. This trial is open at multiple institutions throughout the UH network.

For more information contact:
Rodney Ellis, M.D. at

Among the nation’s leading academic medical centers, University Hospitals Cleveland Medical Center is the primary affiliate of Case Western Reserve University School of Medicine, a nationally recognized leader in medical research and education.

U.S. News & World Report Best Hospitals 2013-2014 Honor Roll - CancerU.S. News & World Report Best Hospitals 2013-2014 Honor Roll

University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine are consistently recognized as two of the premier institutions in the nation, according to U.S. News & World Report’s annual rankings.

Need to Refer a Patient?

Click here for Patient Referrals

Stanton Gerson

Stan Gerson, MD
Director, University Hospitals Seidman Cancer Center Director, Case Comprehensive Cancer Center Director, National Center for Regenerative Medicine

Neal Meropol

Neal Meropol, MD
Chief, Division of Hematology and Oncology Associate Director for Clinical Programs University Hospitals Seidman Cancer Center at UH Cleveland Medical Center Associate Director for Clinical Research Case Comprehensive Cancer Center

New Mobile App for Clinical Trials

UH Seidman Cancer Center has launched a clinical trials search website and mobile-device app developed especially for cancer patients. These new tools provide intuitive interfaces with easy-to-understand language for browsing more than 150 available cancer clinical trials offered in collaboration with the Case Comprehensive Cancer Center. To date, hundreds of patients have taken advantage of these new search capabilities, directing them to clinical trials where appropriate, or to a nurse who answers their questions.